- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterOncoLink at ASCO 2001: Monday, May 14
 |
| South-side view of the Moscone Center, the site of the 2001 ASCO Convention. |
|
A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative oncology Group (ECOG) trial
Presenter: J. Berlin Affiliation: ECOG, USA Background: The vast majority of patients with pancreatic cancer are diagnosed with locally advanced unrespectable or advanced disease for which there is no curative therapy. Many chemotherapeutic ... |
|
|
A randomized Comparison of Radiofrequency Thermal Ablation and Percutaneous Ethanol Injection for the Treatment of Small Hepatocellular Carcinoma
Presenter: H. P. Allgaier/M. Olschewski Affiliation: University of Pisa, Pisa, Italy Background: Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide. Approximately 80% of patients are inoperable at the time of diagnosis.... |
|
|
Clinicians' Assessment Of Quality Of Life (QOL) In Outpatients With Advanced Cancer: How Accurate Is Our Prediction? A Hoosier Oncology Group Study
Presenter: Michael L. Titzer Affiliation: Indiana University Cancer Center and the Walther Cancer Institute, Indianapolis, IN Background: Cancer and its related symptoms, such as depression and fatigue, can have substantial impact on a cancer... |
|
|
Effect Of An SSRI Antidepressant On Fatigue And Depression In Seven Hundred Thirty-Eight Cancer Patients Treated With Chemotherapy: A URCC CCOP Study
Presenter: Gary R. Morrow Affiliation: University of Rochester Cancer Center, Rochester, NY Background: Fatigue can significantly interfere with a cancer patient's ability to fulfill daily responsibilities and enjoy everyday life. It commonly... |
|
|
Evaluation Of The Safety And Efficacy Of An Oral Molecularly-Targeted Therapy, STI-571, In Patients (PTS) With Unresectable Or Metastatic Gastrointestinal Stromal Tumors (GISTS) Expressing C-KIT (CD117)
Presenter: Charles D. Blanke Affiliation: Oregon Health Sciences University, Portland, OR Background: GISTs are cancers which arise from intestinal cells in the abdomen and are characterized by expression of the proto-oncogene c-kit. c-KIT... |
|
|
Fluoxetine Versus Placebo In Advanced Cancer Outpatients: A Placebo-Controlled, Double-Masked Trial Of The Hoosier Oncology Group
Presenter: Michael Jordan Fisch Affiliation: UT/MD Anderson Cancer Center, Houston, TX Background: Depressive symptoms are prevalent in advanced cancer patients, and no standard of care exists regarding assessment and management of this clinical... |
|
|
Gemcitabine-Oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a Gercor Multicenter phase II study
Presenter: C. Louvet Affiliation: Hospital St-Antoine, Paris France Background: Gemcitabine has been shown to be an active agent in the treatment of pancreatic cancer. Some preclinical data showed that the combination of gemcitabine with... |
|
|
International Symposium Takes a Global Look at Treatment for Advanced Breast Cancer
What's the single biggest risk factor for dying of breast cancer, both in the U.S. and worldwide? Poverty, according to a series of presentations given by international researchers at ASCO this morning. Oncologists from the United States,... |
|
|
PELF is More Active than FAMTX in Metastatic Gastric Carcinoma (MGC)
Presenter: G. Cocconi Affiliation: Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy Background: Most patients with gastric cancer in the United States are found at the time of diagnosis to have advanced disease. The prognosis... |
|
|
Phase III Trial To Preserve The Larynx: Induction Chemotherapy And Radiotherapy Versus Concomitant Chemoradiotherapy Versus Radiotherapy Alone, Intergroup Trial R91-11
Presenter: Arlene A. Forastiere Affiliation: Intergroup Background: Induction chemotherapy (IC) followed by radiation has been the standard of treatment for advanced laryngeal carcinoma. In the landmark study of the VA laryngeal trail. (NEJM... |
|
|
Recombinant Human Keratinocyte Growth Factor (RHUKGF) Prevents Chemotherapy-Induced Mucositis In Patients With Advanced Colorectal Cancer: A Randomized Phase II Trial
Presenter: Stephen John Clarke Affiliation: Royal Prince Alfred Hospital, Camperdown, Australia Background: Oral mucositis in cancer patients receiving chemotherapy can lead to dose reduction and/or treatment breaks, both of which could have a... |
|
|
Second Primary Neoplasms (SPNS) Of The Central Nervous System (CNS) In Survivors Of Childhood Cancer - A Report From The Childhood Cancer Survivor Study (CCSS)
Presenter: J. Neglia Affiliation: Childhood Caner Survivor Study, University of Minnesota, Minneapolis, MN Background: Second neoplasms of the CNS are well- recognized events among survivors of childhood cancer, often following leukemia or... |
|
|
STI 571, An Active Drug In Metastatic Gastro Intestinal Stromal Tumors (GIST), An EORTC Phase I Study
Presenter: Allan T. Van Oosterom Affiliation: EORTC Soft Tissue and Bone Sarcoma Group, Brussels, Belgium Background: The overall survival for patients with GISTs is poor with an estimated 10 to 20 month median survival in patients with... |
|
|
Surgical Resection with or without pre-operative chemotherapy in oesophageal cancer: an updated analysis of a randomized controlled trial conducted by the UK Medical Research Council Upper GI Tract Cancer Group
Presenter: P. Clark Affiliation: MRC Clinical Trials Unit, London, UK Background: The poor survival of patients with clinically localized squamous cell or adenocarcinoma of the esophagus suggests that occult dissemination of disease is... |
|
|
SWOG 8710 (INT-0080): Randomized Phase III Trial of Neoadjuvant MVAC+Cystectomy Versus Cystectomy Alone in Patients With Locally Advanced Bladder Cancer
Presenter: R.B. Natale Affiliation: SWOG Background: Radical cystectomy has been the gold standard for the treatment of locally advanced bladder cancer. However, 50-60% develop recurrent or metastatic disease after cystectomy. It has been ... |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
